Full text is available at the source.
Lancet (London, England)···
MEDI0382, a drug targeting appetite and blood sugar control, tested in overweight and obese type 2 diabetes patients in a controlled dose study
Updated
Abstract
MEDI0382 treatment resulted in a 32.78% reduction in glucose levels compared to a 10.16% reduction with placebo.
- Patients receiving MEDI0382 experienced a significant decrease in glucose levels after a mixed-meal tolerance test.
- Bodyweight reduction was significantly greater in the MEDI0382 group, averaging a loss of 3.84 kg compared to 1.70 kg in the placebo group.
- The occurrence of treatment-emergent adverse events was similar between the MEDI0382 and placebo groups.
- Gastrointestinal disorders and decreased appetite were more common in the MEDI0382 group.
- No severe adverse events (grade 3 or worse) occurred in the MEDI0382 group, while two occurred in the placebo group.
Simplified
BACKGROUND: Weight loss is often key in the management of obese or overweight patients with type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight loss. We aimed to assess the efficacy, tolerability, and safety of treatment with MEDI0382, a balanced glucagon-like peptide-1 and glucagon receptor dual agonist developed to provide glycaemic control and weight loss, in patients with type 2 diabetes.
METHODS: This randomised, placebo-controlled, double-blind, combined multiple-ascending dose (MAD) and phase 2a study was done at 11 study sites (hospitals and contract research organisations) in Germany. We enrolled patients aged 18-65 years with controlled type 2 diabetes (glycated haemoglobin A[HbA] levels of 6·5-8·5% at screening) and a body-mass index between 27 kg/mand 40 kg/m. An interactive web-response system was used to randomly assign patients to receive MEDI0382 or placebo. Patients were randomly assigned 2:1 in cohorts A-C and 3:1 in cohorts D and E in the MAD portion of the study, and 1:1 in the phase 2a portion. Randomisation was done by a contracted third-party operator who was not involved in the clinical operations of the study. The pharmacists, participants, and study site personnel involved in treating and assessing participants were masked to treatment allocation. Patients received once-daily subcutaneous injections of the study drug at doses of no more than 300 μg for 22 days or less in the MAD portion of the study, and a dose of no more than 200 μg for 41 days or less in the phase 2a portion. The two primary endpoints of the phase 2a portion were the change from baseline to day 41 in glucose area under the curve at 0-4 h (AUC) after a mixed-meal tolerance test (MMTT), assessed in all participants who received at least one dose of study drug and whose measurements were taken at baseline and day 41, and change from baseline in bodyweight, assessed in the intention-to-treat (ITT) population. Safety analyses were done in all participants who received any study drug analysed according to the treatment they received. This study is registered with ClinicalTrials.gov, number NCT02548585. 1c1c0-4 h2 2
FINDINGS: Patients were recruited between Dec 9, 2015, and Feb 24, 2017. 61 patients were randomly assigned to the MAD part of the study (42 to MEDI0382 and 19 to placebo). 51 patients were randomly assigned to the phase 2a part, of whom 25 were randomly assigned to MEDI0382 and 26 to placebo. In the phase 2a study, three patients in the MEDI0382 group and one in the placebo group discontinued, all as a result of adverse events. 22 (88%) patients in the MEDI0382 group and 25 (96%) in the placebo group received at least one dose and had measurements taken at baseline and day 41. Glucose AUCpost MMTT decreased significantly with MEDI0382 versus placebo (least squares [LS] mean -32·78% [90% CI -36·98 to -28·57] vs -10·16% [-14·10 to -6·21], and the mean difference was -22·62% [-28·40 to -16·85]; p<0·0001). In the ITT population, reduction in bodyweight was significantly greater with MEDI0382 than with placebo (LS mean -3·84 kg [90% CI -4·55 to -3·12] vs -1·70 kg [-2·40 to -1·01] and mean difference of 2·14 kg [-3·13 to -1·31]; p=0·0008). The proportion of patients who had a treatment-emergent adverse event (TEAE) was similar between treatment groups (22 [88%] of 25 in the MEDI0382 group vs 23 [88%] of 26 in the placebo group); gastrointestinal disorders (18 [72%] vs 13 [40%]) and decreased appetite (five [20%] vs none) occurred more frequently with MEDI0382 than placebo. No participants in the MEDI0382 group had a grade 3 or worse TEAE (vs two [8%] in the placebo group). 0-4 h
INTERPRETATION: MEDI0382 has the potential to deliver clinically meaningful reductions in blood glucose and bodyweight in obese or overweight individuals with type 2 diabetes.
FUNDING: MedImmune.
Related papers
Jun '23
Retatrutide, a drug targeting three hormone receptors, for people with type 2 diabetes in a controlled US clinical trial
top 1% journal
cited by 344 papers
randomized controlled trial
Oct '18
Safety and effectiveness of LY3298176, a new drug targeting two hormone receptors, in people with type 2 diabetes: a controlled phase 2 trial
top 1% journal
cited by 714 papers
randomized controlled trial
Nov '22
LY3437943, a new drug activating three hormone receptors, tested in people with type 2 diabetes in a controlled early-stage trial with increasing doses
top 1% journal
cited by 176 papers
randomized controlled trial
Mar '21
Weekly Semaglutide 2.4 mg for Adults with Overweight or Obesity and Type 2 Diabetes: A Controlled Clinical Trial
top 1% journal
cited by 1,112 papers
randomized controlled trial
Dec '15
Liraglutide's effectiveness and safety for overweight adults with type 1 diabetes and poor blood sugar control
top 1% journal
cited by 155 papers
randomized controlled trial
Jun '18
Safety and tolerability of MEDI0382, a drug activating both GLP-1 and glucagon receptors, in a single dose given to healthy volunteers
top 20% journal
cited by 68 papers
randomized controlled trial
Dec '18
Early study testing different doses of MEDI4166, a combined cholesterol-lowering and blood sugar control drug, in overweight or obese people with type 2 diabetes
top 2% journal
cited by 14 papers
randomized controlled trial
Jan '17
Effectiveness and safety of once-weekly semaglutide alone compared to placebo in people with type 2 diabetes
top 1% journal
cited by 636 papers
randomized controlled trial
Apr '17
Weekly semaglutide compared to daily sitagliptin added to diabetes pills in type 2 diabetes over 56 weeks: a safety and effectiveness trial
top 1% journal
cited by 420 papers
randomized controlled trial
Aug '18
Effectiveness and safety of semaglutide versus liraglutide and placebo for weight loss in people with obesity
top 1% journal
cited by 696 papers
randomized controlled trial